BRCA1 and prostate cancer: Thus, BRCA1/2 sequencing is more and more commonly ordered by oncologists as a test performed on tDNA not only for patients with ovarian cancer but also for specific patients with prostate cancer and pancreatic cancer in whom such therapy could be considered (McAlarnen et al., 2021; Szczerba et al., 2021).